Compositions for treating a sleep disorder or modifying or improving the sleep-wake cycle in a subject are disclosed herein. In some examples, the composition can comprise one or more sleep promoting active agents, one or more sleep quality active agents, one or more sleep recovery active agents, and optionally one or more next day active agents. The composition can provide an immediate burst release of the one or more sleep promoting active agents, a delayed burst or delayed sustained release of the one or more sleep quality active agents, a delayed burst or delayed sustained release of the one or more sleep recovery active agents, and a delayed burnt or delayed sustained release of the one or more next day active agents. The composition can be provided as a daily oral uni-dosage form. Methods of making and using the compositions are also provided.

The present invention relates to compositions and methods for potentiating glutathione enhancement for use in brain health. In particular, the compositions and methods of the invention are beneficial for use in subjects in need of increasing motivational performance and/or mental energy, functions that may be decreased upon stress and anxiety.

Methods of treating human papillomavirus (HPV)-induced conditions, HPV-induced lesions, or HPV-infected cells. The method involves administering one or more artemisinin-related compounds and one or more histone deacetylase (HDAC) inhibitors. In addition, treatment regimens involving the use of artemisinin-related compounds and HDAC inhibitors, and kits comprising pharmaceutical compositions of artemisinin-related compounds and HDAC inhibitors.

Methods of treating human papillomavirus (HPV)-induced conditions, HPV-induced lesions, or HPV-infected cells. The method involves administering one or more artemisinin-related compounds and one or more histone deacetylase (HDAC) inhibitors. In addition, treatment regimens involving the use of artemisinin-related compounds and HDAC inhibitors, and kits comprising pharmaceutical compositions of artemisinin-related compounds and HDAC inhibitors.

Methods of treating human papillomavirus (HPV)-induced conditions, HPV-induced lesions, or HPV-infected cells. The method involves administering one or more artemisinin-related compounds and one or more histone deacetylase (HDAC) inhibitors. In addition, treatment regimens involving the use of artemisinin-related compounds and HDAC inhibitors, and kits comprising pharmaceutical compositions of artemisinin-related compounds and HDAC inhibitors.

The present invention provides methods, compositions, combinations, and kits for treating a subject with a viral infection (e.g., COVID-19) by administering or providing an estrogen receptor modulator and an anti-inflammatory agent or by administering or providing an anti-inflammatory agent (e.g., melatonin) to the subject.

The present invention provides methods, compositions, combinations, and kits for treating a subject with a viral infection (e.g., COVID-19) by administering or providing an estrogen receptor modulator and an anti-inflammatory agent or by administering or providing an anti-inflammatory agent (e.g., melatonin) to the subject.

The present invention provides methods, compositions, combinations, and kits for treating a subject with a viral infection (e.g., COVID-19) by administering or providing an estrogen receptor modulator and an anti-inflammatory agent or by administering or providing an anti-inflammatory agent (e.g., melatonin) to the subject.

Abstract: This document relates to methods and materials for assessing biological aging. For example, methods and materials that can be used to determine if a mammal (e.g., a human) has an advanced biological age, is at risk of developing one or more adverse outcomes (e.g., adverse outcomes associated with medical intervention at an advanced biological age) following a medical intervention, and/or is likely to be responsive to one or more senotherapeutic agents are provided herein. In some cases, methods and materials for using one or more senotherapeutic agents to improve one or more outcomes for a mammal following a medical intervention (e.g., surgery) are also provided.

Abstract: This document relates to methods and materials for assessing biological aging. For example, methods and materials that can be used to determine if a mammal (e.g., a human) has an advanced biological age, is at risk of developing one or more adverse outcomes (e.g., adverse outcomes associated with medical intervention at an advanced biological age) following a medical intervention, and/or is likely to be responsive to one or more senotherapeutic agents are provided herein. In some cases, methods and materials for using one or more senotherapeutic agents to improve one or more outcomes for a mammal following a medical intervention (e.g., surgery) are also provided.